Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALIBER: Mitomycin C chemoresection in low-risk NMIBC
NCT02070120Phase 2Unknown
- Sponsor
- The Institute of Cancer Research
- Start
- Oct 2014
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mitomycin c in Non-muscle-invasive bladder cancer (NMIBC), sponsored by The Institute of Cancer Research. Primary endpoint: Complete response rate at 3 months. Status: unknown.
02
Drugs
mitomycin c
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT02070120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02070120.